Kyowa to exclusively market Quetiapine Fumarate Extended-Release tablets in Japan
Osaka (Japan): Pharma Major Lupin Limited (Lupin) announced that its Japanese subsidiary Kyowa Pharmaceutical Industry Co., Ltd. (Head Office: Osaka, Japan; President & Representative Director: Ray Tsunoda; hereafter referred as “Kyowa”) and Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) have entered into an agreement providing Kyowa the exclusive right to distribute and promote extended-release tablets of quetiapine fumarate in Japan. Astellas submitted a new drug application (NDA) with the Ministry of Health, Labour and Welfare in Japan for extended-release tablets of quetiapine fumarate for the indication of improvement of depressive symptoms associated with bipolar disorder.
When Astellas obtains an approval for the new drug application of extended-release tablets of quetiapine fumarate, based on the agreement, Kyowa will exclusively distribute and promote the products in Japan.
Dr. Fabrice Egros, President – Asia Pacific & Japan, Lupin Limited commented, “Following Kyowa’s recent acquisition of long-listed products from Shionogi & Co., Ltd., the Astellas agreement reinforces Kyowa’s transition toward a hybrid pharmaceutical specialty care company and bolsters its leadership in the CNS space in Japan. Post regulatory approval for the product, we hope to bring to market a new solution for the treatment of depressive symptoms associated with bipolar disorder addressing unmet need for patients as well as provide additional treatment option for health care professionals in Japan.”
Founded in 1954, Kyowa Pharmaceutical Industry Co., Ltd. is a pharmaceutical company developing and manufacturing Branded & Generic pharmaceutical products for patients in the Japanese Market. With sales of JPY 25 billion for the fiscal year ended March 2016, Kyowa is amongst the fastest growing pharmaceutical companies in Japan, a market leader in the Central Nervous System – Neurology space and has strong presence in Cardiovascular, Gastroenterology and Injectable therapy segments. The company covers 94% of the 1,400 psychiatric hospitals in Japan. Kyowa enjoys strong brand equity in the psychiatric and neurological therapy segments, well known for its high quality pharmaceutical product portfolio under the “Kyowa AMEL” brand franchise.
Kyowa is a Japanese subsidiary of Lupin Limited. For more information, please visit our website at http://www.kyowayakuhin.co.jp
About Lupin Limited
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
Lupin is the 5th and the 6th largest generics pharmaceutical company by market capitalization (December 31st, 2016, Bloomberg) and sales globally (September 30th, 2016, Bloomberg). The Company is the 5th largest pharmaceutical player in the US by prescriptions (4.68% market share – IMS Health, National Prescription Audit, March 2016); the 2nd largest Indian pharmaceutical company by revenues; the 6th largest generic pharmaceutical player in Japan and the 4th largest generic pharmaceutical company in South Africa (IMS Health, March 2016).
For the financial year ended 31st March, 2016, Lupin’s Consolidated sales and Net profit stood at Rs. 137,579 million (USD 2.1 billion) and Rs. 22,607 million (USD 345 million) respectively. Please visit http://www.lupin.com for more information.
CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055
For further information or queries please contact –
For Lupin Limited
Head –IR and M&A
Ph: +91 9167241531 / 022 66402409